How will Novartis price its groundbreaking CAR-T med? R&D exec offers some clues

Novartis has an FDA action date on CAR-T drug CTL019 in early October.

The FDA isn't the only hurdle for Novartis' forthcoming CAR-T therapy, which could be the world's first. There's pricing and access, too. Drugs in this new class of one-time treatments are expected to be ultra-expensive, so the company is working up pricing and payment strategies now.

Novartis’ CTL019 is under review to treat pediatric and young adult relapsed and refractory B-cell acute lymphoblastic leukemia (ALL), with the FDA’s action date set for early October. In the meantime, it's using stem cell transplants as a benchmark for pricing and considering pay-for-performance deals to make the medications accessible for payers and patients alike, R&D chief Vas Narasimhan told Bloomberg.

CAR-T therapies are individualized treatments manufactured from a patient's own T cells, with the promise of a cure. As one-time treatments, just as gene therapies are, they're expected to be among the world's most costly drugs if approved. Novartis is in a hot race to approval with Kite Pharma, with other would-be CAR-T products coming up behind.

RELATED: As Novartis preps for first CAR-T FDA AdComm, Juliet data revealed

Earlier this year, England’s cost watchdogs NICE ran the numbers and found that CAR-T medications could be worth up to $649,000, assuming that patients gain 10 quality-adjusted life years over the current standard of care. At the time, a Novartis spokesperson said "it is too early for us to comment on pricing; however, we will at the time of approval."

Asked to confirm the Narasimhan's remarks on pricing and payment, a Novartis spokesperson reiterated that it’s “too early for us to comment on pricing.” Stem cell transplants and follow-up treatment can cost upwards of $800,000.

Narasimhan’s statements come just days after an investor and analyst meeting for Novartis, where the company’s management talked up CAR-T prospects. In their coverage of the meeting, Jefferies analysts wrote that they “detected a strong change in tone and optimism around the CAR-T program.”

RELATED: CAR-T drugs worth up to $649K in childhood leukemia, says U.K. report

In a note afterward, Jefferies analyst Jeffrey Holford wrote that Novartis management was “enthusiastic about the ability to price CAR-T at very attractive levels as well as to also potentially move into the [chronic lymphocytic leukemia] indication, multiple myeloma and solid tumors.” Those indications would be big expansions, potentially adding thousands more patients eligible for treatment.

Novartis plans a filing in diffuse large B-cell lymphoma this year, according to the pipeline report on its website. On Wednesday, the drugmaker released interim findings in relapsing/remitting diffuse large B-cell lymphoma patients showing a 3-month overall response rate in 45% of the patients. The med hit its primary endpoint.

RELATED: The world's most pricey drugs, from a $1.2M gene therapy to a $450K lymphoma med

An April ranking of the world’s costliest meds determined that uniQure’s gene therapy Glybera topped the industry at $1.2 million, but low demand forced the company to pull the plug on that med since the numbers were compiled. Recent pricey launches include Biogen’s spinal muscular atrophy med Spinraza, which costs $750,000 for the first year and half that for subsequent years, and BioMarin’s Brineura to treat the ultrarare CLN2 disease, at $702,000.

Novartis is vying against Kite Pharma, Juno and others in the groundbreaking CAR-T field. Kite’s axicabtagene ciloleucel is due for an FDA action by Nov. 29 in refractory non-Hodgkin's lymphoma, according to BioPharmCatalyst. EvaluatePharma analysts have pegged the Kite drug, KTE-C19, as one of the top 10 drug launches of 2017.

Suggested Articles

Merck & Co. joined the pack in 2018 by hiring Jim Scholefield as its first chief digital officer. Now, less than two years in, he's moving on.

Teva is counting on Austedo for growth amid challenges elsewhere, and this week, the drug failed two trials in Tourette syndrome.

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.